Crovela BioPharm

Crovela is a preclinical-stage biotechnology company focused on developing next-generation complement inhibitors for the treatment of complement-mediated diseases, with an initial focus on ophthalmology. The company's proprietary platform utilizes a targeting moiety derived from Complement Receptor 2 (CR2) to direct potent complement inhibitors specifically to sites of active tissue injury and complement activation. This "targeted" approach aims to provide superior efficacy and a better safety profile compared to systemic or non-targeted inhibitors by concentrating the therapeutic effect where it is needed most. Crovela's lead program, CVL-101, is a recombinant fusion protein being developed for the treatment of geographic atrophy secondary to age-related macular degeneration. Founded by world-renowned experts in complement biology from the University of Colorado, the company is backed by a syndicate of leading life science investors. Crovela is currently advancing its pipeline through IND-enabling studies to bring precision medicine to the complement space.